Contamination of propofol, in an emulsion formulation, has been associated with infective complications. Local anaesthetics,some of which are known to have antibacterial properties, are frequently added to the solution to reduce pain on injection.
Propofol (2,6-diisopropylphenol ) is an intravenous anaesthetic drug that is poorly soluble in water and presented as an emulsion: 1% propofol, 10% soybean oil, 1.2% egg phosphatid, 0.25% glycerol 1, 2 . It has been shown that this emulsion can support bacterial growth and contamination of propofol emulsion with common pathogens results in microbial proliferation. Propofol must be prepared for administration in an aseptic manner and the effects of contamination may be exaggerated if there is a delay in administration after the ampoule is opened 3 .
Propofol emulsion commonly causes pain on IV injection. This may be reduced by adding local anaesthetic, frequently lignocaine, to the solution 4 . The antimicrobial activity of local anaesthetics was first reported by Jonnesco in 1909 and later was confirmed by the investigators, particularly for lignocaine 5, 6 . It has been suggested that local anaesthetics prevent the propagation of the electrical impulse and disrupt the bacterial membrane potential through depolarization of the cytoplasmic membrane 7 .
We aimed to investigate whether or not lignocaine added to different concentrations of propofol would prevent bacterial proliferation.
MATERIALS AND METHODS
Standard strains of Staphylococcus aureus (American Type Culture Collection, ATCC 29068), Staphylococcus epidermidis (ATCC 12228), Escherichia coli (ATCC 25922) and Pseudomonas aeruginosa (ATCC 27853) were used. Several colonies of each isolate were added to blood agar culture medium and incubated at 35°C for 24 hours. After incubation, 3 to 4 colonies from each isolate were inoculated into 3 ml Mueller Hinton broth. Further dilutions of the inoculum were made in 0.9% saline, adapted to a McFarland standard concentration of 0.5. The final concentration was 5 x10 5 colonies. The number of colony-forming units (CFU) per milliliter was determined.
The lignocaine-propofol test mixtures (20 ml) were prepared under aseptic conditions. The quantity of lignocaine in the mixtures ranged from 1 ml to 20 ml of 2%, producing a range of lignocaine concentration of 0.1 to 2%. A sample of propofol and saline 20 ml without lignocaine was also prepared (Table 1) .
Sterile test tubes were set up, in duplicate, with 2 ml of each drug combination. A 100 µl inoculum suspension adjusted for each of the bacteria was added separately to each tube and mixed gently. For each isolate, 100 µl of inoculum suspension was added to blood agar medium (5% sheep blood agar, Diamed). Isolates were left to incubate at 37°C for 24 hours. At 2, 5 and 24 hours, a 100 µl sample of each tube was taken and again inoculated into blood agar medium and left to incubate at 37°C for 24 hours. After incubation, the bacteria produced were counted and the number of CFUs were established for each microorganism. Analysis of variance (ANOVA) with a post hoc t-test was used for data analysis. A probability of P<0.05 was taken to indicate statistical significance.
RESULTS
In all preparations there was an increase in the number of CFU of the four organisms 2, 5 and 24 hours after inoculation except for S. aureus (P<0.05). There was no significant difference in the number of CFUs between 2 and 5 hours after inoculation for this microorganism (Figure 1 ). With E. coli a significant decline in CFUs in the mixture of 1% lignocaine in propofol and in 2% lignocaine alone was observed compared with propofol alone (P<0.05). The number of CFUs of E. coli in the mixtures of 0.1% and 0.5 % lignocaine in propofol was not significantly lower than propofol alone (Figure 2 ). With S. epidermidis a significant reduction in the number of CFUs was found only in 2 % lignocaine (P<0.05) ( Figure 2 ).
With S. aureus and P. aeruginosa a significant decline was observed in CFU numbers of Group V compared with propofol alone and 0.1% lignocaine in propofol (P<0.05) ( Figure 2 ). The mixtures of 0.1, 0.5 and 1% lignocaine did not show a significant reduction in CFU numbers of these microorganisms compared with propofol and saline. There was no statistically significant difference in the number of CFU between propofol alone and saline.
DISCUSSION
Propofol in the emulsion formulation supports bacterial growth 3 . Extrinsically contaminated propofol has been associated with multiple infective complications. These are postsurgical infections including either bacteraemia or wound infection 3,8,9 . Veber et al described a severe outbreak of sepsis that underscores the need for aseptic techniques in the handling of this commonly used anaesthetic agent 10 . This report described four patients developing Klebsiella septicemia within hours of surgery performed in the same operating room. Kuehnert et al documented five patients who developed S. aureus septicemia after IV injection of a propofol emulsion for electroconvulsive therapy 11 .
It is well known that propofol is associated with pain on injection 12, 13 . The addition of lignocaine to propofol for the relief of pain is a common anaesthetic practice. It was recommended that lignocaine 10 mg added to propofol 20 ml (approximately 0.05% lignocaine) reduces the pain of injection and that larger doses of lignocaine may destabilize the emulsion 14 . Lilley et al suggested that larger doses are more effective and no problem of chemical incompatibility occurs when lignocaine 20 mg is added to propofol 20 ml (approximately 0.1% lignocaine) 15 . We therefore used 0.1% lignocaine as the lowest concentration in our study.
Previous studies have shown the inhibitory effects of lignocaine on various Gram positive and Gram 16, 17 . Most of this work has been related to the effect that topical anaesthetics may have on the recovery of bacteria in samples taken during bronchoscopy 18 , ophthalmological procedures 18, 19 or with biopsy of dermal lesions 16 . The exact mechanism of the antimicrobial action of lignocaine is not known, but may be due to an effect on microbial cell membrane structure or function or pH alteration 4, 6, 20, 21 .
Our findings show that propofol supports the growth of E. coli, S. aureus, S. epidermidis and P. aeruginosa and that there was a progressive reduction in colony counts of all microorganisms with the increasing concentrations of lignocaine. The recommended dose of lignocaine of 20 mg in propofol 20 ml (0.1% lignocaine) did not produce significantly lower colony counts compared with colony counts in propofol alone. It seems that this concentration of lignocaine reduces the rate of bacterial growth in propofol but does not prevent it completely. Wachowski et al suggested that lignocaine 0.5% alone was not statistically different from saline in supressing the growth of bacteria 1 . Vidovich et al concluded that there was no significant difference in microbial growth in propofol with and without lignocaine 8 . In contrast, Gagraj et al reported the inhibitory effect of 0.005% lignocaine particularly against E. coli in propofol emulsion 4 .
It has been suggested that certain conditions can influence the inhibitory effects. These conditions are the dosage of the anaesthetic, its dilution by specimen collection diluents, contact time with the organism and number and types of microorganisms present in cultures. Therefore these inconsistencies may be a result of different techniques, different serotypes of microorganisms and growth mediums 4, 16, 18 .
Our results suggest that 0.1 to 2% lignocaine may limit but not prevent bacterial proliferation. Therefore, to avoid severe life-threatening complications due to bacterial growth in contaminated propofol, it is important to follow the recommendations for propofol use and not to rely on added lignocaine to prevent infective complications.
